Compare AU
Compare DRUG vs. HGBL
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the BetaShares Global Healthcare ETF - Currency Hedged (DRUG) and the BetaShares Global Shares ETF - Currency Hedged (HGBL). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
DRUG | HGBL | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 63 | 59 |
Median incremental investment | $967.00 | $3,998.73 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,921.92 | $15,561.00 |
Average age group | 26 - 35 | 26 - 35 |
Key Summary
DRUG | HGBL | |
|---|---|---|
Strategy | DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars. | HGBL.AX was created on 2023-05-16 by BetaShares. The fund's investment portfolio concentrates primarily on total market equity. The investment objective of each Fund is to provide an investment return, before fees and expenses, that aims to track the performance of the relevant Index. |
Top 3 holdings | CHF - SWISS FRANC (0 %) AUD - AUSTRALIA DOLLAR (0 %) DKK - DANISH KRONE (0 %) | Betashares Global Shares ETF (100.00 %) |
Top 3 industries | Other (75.53 %) Communication Services (33.53 %) Health Care (24.47 %) | Other (29.91 %) Information Technology (23.98 %) Health Care (8.49 %) |
Top 3 countries | United States (71.71 %) Switzerland (8.14 %) Denmark (6.30 %) | United States (71.69 %) Japan (6.93 %) United Kingdom of Great Britain and Northern Ireland (3.99 %) |
Management fee | 0.57 % | 0.11 % |
Key Summary
DRUG | HGBL | |
|---|---|---|
Issuer | BetaShares | BetaShares |
Tracking index | Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD | Solactive GBS Developed Markets ex Australia Large & Mid Cap Index - AUD - Benchmark TR Net |
Asset class | ETF | ETF |
Management fee | 0.57 % | 0.11 % |
Price | $8.25 | $68.08 |
Size | $182.401 million | $1.064 billion |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 1.90 % | 0.43 % |
Market | ASX | ASX |
First listed date | 08/08/2016 | 17/05/2023 |
Purchase fee | $6.50 | $6.50 |
Community Stats
DRUG | HGBL | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 63 | 59 |
Median incremental investment | $967.00 | $3,998.73 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,921.92 | $15,561.00 |
Average age group | 26 - 35 | 26 - 35 |
Pros and Cons
DRUG | HGBL | |
|---|---|---|
Pros |
|
|
Cons |
|
|
DRUG | HGBL |
|---|---|
Higher exposure to US market | Lower exposure to US market |
Higher management fee | Lower management fee |
Higher price growth | Lower price growth |
Higher distribution yield | Lower distribution yield |